• Diagnostics and treatment regimens formulated for pediatric TB patients generally are not available.
  • Support for basic science contributing to drug discovery is lacking. Improved connections among medicinal chemists, microbiological laboratories, and clinical investigators could hasten drug discovery.
  • Facilities for the biosafety level-3 laboratories needed for some MDR TB research in Russia are limited.
  • The TB strains used as standards in the West differ somewhat from those used as standards in Russia. These differences should be considered in comparing results of tests of diagnostics and drug effectiveness.
  • Diagnostic drug susceptibility testing needs to be harmonized across Russia and, in particular, with new drug developers.
  • Increased communication and collaboration among investigators within and outside of Russia could be beneficial to all participants. For example, the importation of reagents, equipment, and microbes is currently a barrier to collaborative research.
  • Research opportunities supported by the National Institutes of Health and other organizations are open to Russian investigators.
  • The clinical trial infrastructure needs to be strengthened for registration studies.
  • Regulatory and bureaucratic bottlenecks need to be removed for chemical entities in Phase I and Phase II clinical trials.
  • Standards of care and approaches to TB treatment need to be harmonized for multicenter trials.
  • Present clinical sites in Russia and other nations need to be sustained and supported for forthcoming global Phase III trials.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement